Day: July 19, 2021

Vow ASA has through its subsidiary Scanship AS been awarded 10 contracts for its clean ship systems for up to 10 cruise ships, where 4 contracts are firm orders at a total value of Euro 8.880.000 and 6 contracts are optional contracts at a total value of Euro13.320.000. Each contract includes the supply of state-of-the-art technology to process garbage, food waste and wastewater onboard cruise ships carrying 1500 people aboard. Scanship has previously delivered and are currently delivering equal systems to 10 cruise ships built by the same yard for the same shipowner on a newbuild program commenced in 2012. The new orders are an extension of this program, where the first equipment delivery for the 11th ship will be in 1Q 2023. “We are very pleased to continue to supply our technology towards one of the largest newbuild programs in the...

Uponor Corporation     Investor news     19 July 2021     09:30 EET Uponor publishes half-year financial report 2021 on 27 July 2021 Uponor Corporation’s half-year financial report 2021 will be published on Tuesday, 27 July 2021 at 08:00 EET. The report will be available on uponorgroup.com after publishing. A live webcast will be arranged for analysts, fund managers, investors, and representatives of the media, starting at 13:00 EET. The webcast, hosted by Jyri Luomakoski, President and CEO, and Minna Yrjönmäki, CFO, can be viewed from https://platform.goodmood.fi/goodmood/uponor/half-year-results-briefing-1-6-2021 or Uponor’s IR app. The recorded webcast can be viewed from the above website and the app shortly after the live webcast. Uponor Corporation Further information:Susanna InkinenVice President, Communications and Corporate ResponsibilityTel....

Final analysis from the phase IIIb STASEY study, including data from 193 people with haemophilia A, further support the benefit/risk profile of Hemlibra, with no new safety signals identified1 STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with haemophilia A with factor VIII inhibitors Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds1Basel, 19 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term...

REGULATED INFORMATIONJTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemicGosselies, Belgium, 19 July 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today provides an update on its two leading ongoing clinical studies. These studies are the pivotal Phase III clinical trial with Bone Therapeutics’ enhanced viscosupplement, JTA-004, targeting osteoarthritic knee pain, and the Phase IIb study with its allogeneic cell therapy product, ALLOB, in patients with difficult-to-heal tibial fractures. The JTA-004 Phase III clinical study, having achieved target patient recruitment in December 2020, has now completed the six-month follow-up...

Saint-Herblain (France) and New York, NY, July 19, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. (NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.   A total of 625 participants, 5 to 65 years of age, have been randomized in the Phase 2 trial to receive VLA15 at Month 0-2-6 or Month 0-6 (200 volunteers each) or placebo at Month 0-2-6 (200 volunteers). The main safety and immunogenicity...

TSXV:BABY.V expects to provide a special business update at the Company conference. Event venue will be announced separately. VANCOUVER, British Columbia, July 19, 2021 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company, invites investors and shareholders to hear a Company update ( “Event”). The Event will be held on October 4th in New York City, at a venue to be announced ahead of the Event with registration and RSVP links. “We are working on some exciting developments we would like to present to shareholders in person, “said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “we look forward to this event and invite both retail and institutional investors to attend our conference”. About Else...

NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. The results showed that two doses of remestemcel-L at days 3-5 conferred durable survival benefit through at least 90 days in the pre-specified subgroup of patients under age 65. Key presentation findings were:Remestemcel-L significantly reduced mortality by 48% at 90 days...